Anesth Analg 2003;96:1316-1319
© 2003 International Anesthesia Research Society
TECHNICAL COMMUNICATION
An Assessment of Different Filter Systems for Extracorporeal Elimination of Bivalirudin: An In Vitro Study
Andreas Koster, MD*,
Derek Chew, MD ,
Marcus Gründel, MD*,
Harald Hausmann, MD ,
Onnen Grauhan, MD ,
Herman Kuppe, MD*, and
Bruce D. Spiess, MD
Departments for *Anesthesia and
Thoracic and Cardiovascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany;
Department of Cardiology, Flinders Medical Center, South Australia, Australia; and
Department of Cardiothoracic Anesthesia, Virginia Commonwealth University, Richmond, Virginia
Address correspondence and reprint requests to Dr. Andreas Koster, Deutsches Herzzentrum Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany. Address e-mail to koster{at}dhzb.de
IMPLICATIONS: Bivalirudin is a new, direct thrombin inhibitor. We investigated the extracorporeal elimination rate of different hemofilters and one plasmapheresis filter for bivalirudin. Our data show that bivalirudin can be effectively eliminated via hemofiltration and plasmapheresis, although there were significant differences in the elimination rates among the filter systems investigated.
This article has been cited by other articles:

|
 |

|
 |
 
I. Apostolidou, M. F. Sweeney, E. Missov, L. D. Joyce, R. John, and R. C. Prielipp
Acute Left Atrial Thrombus After Recombinant Factor VIIa Administration During Left Ventricular Assist Device Implantation in a Patient with Heparin-Induced Thrombocytopenia
Anesth. Analg.,
February 1, 2008;
106(2):
404 - 408.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. F. Merry
Focus on Thrombin: Alternative Anticoagulants
Seminars in Cardiothoracic and Vascular Anesthesia,
December 1, 2007;
11(4):
256 - 260.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Koster, T. Hentschel, T. Groman, H. Kuppe, R. Hetzer, S. Harder, and K.-G. Fischer
Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery
J. Thorac. Cardiovasc. Surg.,
May 1, 2007;
133(5):
1376 - 1377.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Cain, B. D. Spiess, M. Nelson, A. Deanda Jr, H. L. McCarthy, and J. A. Green
Bivalirudin Anticoagulation for a Patient with Hypercoagulable Immune Syndromes Undergoing Mitral Valve Surgery
Ann. Thorac. Surg.,
June 1, 2006;
81(6):
2308 - 2310.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Koster, D. Chew, F. Merkle, M. Gruendel, M. Jurmann, H. Kuppe, and R. Oertel
Extracorporeal Elimination of Large Concentrations of Tirofiban by Zero-Balanced Ultrafiltration During Cardiopulmonary Bypass: An In Vitro Investigation
Anesth. Analg.,
October 1, 2004;
99(4):
989 - 992.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Stratmann, A. M. deSilva, E. E. Tseng, J. Hambleton, M. Balea, A. J. Romo, M. J. Mann, N. L. Achorn, W. F. Moskalik, and C. W. Hoopes
Reversal of Direct Thrombin Inhibition After Cardiopulmonary Bypass in a Patient with Heparin-Induced Thrombocytopenia
Anesth. Analg.,
June 1, 2004;
98(6):
1635 - 1639.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Green, C. L. Cooper, O. A. Falcucci, A. Safwat, T. Slaughter, B. D. Spiess, and V. G. Nielsen
Argatroban for Off-Pump Coronary Artery Bypass Surgery * Response
Anesth. Analg.,
October 1, 2003;
97(4):
1201 - 1202.
[Full Text]
[PDF]
|
 |
|
|